The invention pertains to fused cyclic compounds having the formula,
##STR1##
wherein G is an optionally substituted aryl or heterocyclo, L is an optional
linker, M is a bond, O, CR7R7 or NR10,
and M is a bond or NR10, with the proviso that at least one
of M or M must be a bond; E is CZ2, CR7CR7,
SO2, POR2, or POOR2; Z1
is O, S, NH, or NR6; Z2 is O, S, NH, or NR6; A1
is CR7 or N; A2 is CR7 or N; Y is J—J—J"
where J is (CR7R7)n and n=0-3, J is a bond
or O, S, SO, SO2, NH, NR6, CO, OCO,
NR1CO, CR7R7, CCR8R8,
R2PO, OPOOR2, OPO2, OSO2, CN,
NHNH, NHNR6, NR6NH, NN, cycloalkyl or substituted
cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted
heterocyclo or aryl or substituted aryl, and J" is (CR7R7)n
and n=0-3; W is CR7R7—CR7R7,
CR8CR8, CR7R7—CO,
NR9—CR7R7, NCR8,
NN, NR9—NR9, cycloalkyl or substituted
cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted
heterocyclo, or aryl or substituted aryl; and O, R2, R6,
R7, R7, R8, R8, R9,
R9, and R10 are as defined in the specification,
to methods of using such compounds in the treatment of nuclear hormone receptor-associated
conditions such as cancer and immune disorders, and to pharmaceutical compositions
containing such compounds.